Skip to Content
Merck
All Photos(1)

Key Documents

925624

Sigma-Aldrich

Redox Responsive Poly(ethylene glycol)-block-poly(ε-caprolactone)

PEG average Mn 5,000, PCL Mn 15,000

Synonym(s):

Block copolymer, PEG-PCL with disulfide linkage, PEG-SS-PCL, Stimuli-responsive

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
CH3O(C2H4O)nC7H12O4S2(C6H10O2)
UNSPSC Code:
12352112
NACRES:
NA.23

form

solid (could be powder/granules/chunks)

Quality Level

mol wt

PCL Mn 15,000
PEG average Mn 5,000

color

white to beige, light yellow

storage temp.

2-8°C

Application

PEG-SS-PCL is a redox responsive, biocompatible, amphiphilic block copolymer composed of a hydrophilic poly(ethylene glycol) (PEG) block and a hydrophobic poly(ε-caprolactone) (PCL) block, with a reducible disulfide linkage between blocks. This polymer can be fabricated into Glutathione (GSH) responsive nanoparticles which can be used as an intracellular drug delivery system.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

pH/redox dual-sensitive nanoparticles based on the PCL/PEG triblock copolymer for enhanced intracellular doxorubicin release.
Cao Y, et al.
Royal Society of Chemistry Advances, 5, 28060-28069 (2015)
Philip Grossen et al.
Journal of controlled release : official journal of the Controlled Release Society, 260, 46-60 (2017-05-26)
The lack of efficient therapeutic options for many severe disorders including cancer spurs demand for improved drug delivery technologies. Nanoscale drug delivery systems based on poly(ethylene glycol)-poly(ε-caprolactone) copolymers (PEG-PCL) represent a strategy to implement therapies with enhanced drug accumulation at

Articles

Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service